Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DAO | P14920 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.32 |
| ▸ | MAOA | P21397 | 1/20 | 0.32 |
| ▸ | MAOB | P27338 | 1/20 | 0.32 |
| ▸ | GPR84 | Q9NQS5 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6542433 | 0.98 | DAO (0.31) | DAOTSHRNAPRTALDH1A1ALOX15 | |
| SCHEMBL5836004 | 0.87 | GPR84 (0.30) | GPR84 | |
| SCHEMBL1650430 | 0.84 | TSHR (0.33) | TSHRALDH1A1GPR84 | |
| Quinoline SCHEMBL10996262 | 0.83 | ALDH1A1 (0.44) | TSHRALDH1A1ALOX15 | |
| SCHEMBL30218272 | 0.80 | GAA (0.35) | ALDH1A1GPR84 | |
| SCHEMBL7984058 | 0.78 | TSHR (0.38) | TSHRALDH1A1 | |
| SCHEMBL7362125 | 0.76 | PTGS2 (0.44) | — | |
| SCHEMBL7974789 | 0.76 | BCHE (0.39) | TSHRALDH1A1 | |
| SCHEMBL4103015 | 0.72 | GPR84 (0.32) | GPR84 | |
| SCHEMBL7362122 | 0.72 | CA1 (0.42) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1289558-A2 | COMBINATIONS OF AN ENDOTHELIN RECEPTOR ANTAGONIST AND AN ANTIEPILEPTIC COMPOUND HAVING PAIN ALLEVIATING PROPERTIES OR ANALGESIC | WARNER-LAMBERT COMPANY LLC (US) | 2003-03-12 | — | — | EP | claimed |
| US-6440962-B2 | CARDIOVASCULAR DISORDERS, ANTIISCHEMIC AGENTS | WARNER-LAMBERT COMPANY | 2002-08-27 | — | — | US | claimed |
| US-20020094980-A1 | Certain benzothiazine dioxide endothelin antagonists and processes for their preparation | BUNKER AMY MAE (US) | 2002-07-18 | — | — | US | claimed |
| WO-2001091736-A2 | COMBINATIONS OF AN ENDOTHELIN RECEPTOR ANTAGONIST AND AN ANTIEPILEPTIC COMPOUND HAVING PAIN ALLEVIATING PROPERTIES OR ANALGESIC | WARNER-LAMBERT COMPANY (US) | 2001-12-06 | — | — | WO | claimed |
| US-20010036944-A1 | Certain benzothiazine dioxide endothelin antagonists and processes for their preparation | BUNKER AMY MAE (US) | 2001-11-01 | — | — | US | claimed |
| EP-0811001-B1 | BENZOTHIAZINE DIOXIDES AS ENDOTHELIN ANTAGONISTS | WARNER LAMBERT CO (US) | 2001-10-31 | — | — | EP | claimed |
| EP-1009743-A1 | CERTAIN BENZOTHIAZINE DIOXIDE ENDOTHELIN ANTAGONISTS AND PROCESSES FOR THEIR PREPARATION | WARNER-LAMBERT COMPANY (US) | 2000-06-21 | — | — | EP | claimed |
| WO-1999012916-A1 | CERTAIN BENZOTHIAZINE DIOXIDE ENDOTHELIN ANTAGONISTS AND PROCESSES FOR THEIR PREPARATION | WARNER-LAMBERT COMPANY (US) | 1999-03-18 | — | — | WO | claimed |
| EP-0267432-B1 | ANTIBACTERIALLY ACTIVE PYRIDO-BENZOTHIAZINE DERIVATIVES WITH LONG TERM ACTION | MEDIOLANUM FARMACEUTICI s.r.l. (IT) | 1991-12-27 | — | — | EP | claimed |
| EP-2499146-B1 | TRICYCLIC PYRAZOL AMINE DERIVATIVES | MERCK SERONO SA (CH) | 2016-09-21 | — | — | EP | disclosed |
| CN-102695710-B | Tricyclic pyrazole sulfonamide derivatives | MERCK SERONO S.A. (CH) | 2015-08-19 | — | — | CN | disclosed |
| US-9073940-B2 | Tricyclic pyrazol amine derivatives | MERCK SERONO SA (CH) | 2015-07-07 | — | — | US | disclosed |
| CN-102695710-A | Tricyclic pyrazol amine derivatives | MERCK SERONO SA | 2012-09-26 | — | — | CN | disclosed |
| US-20120238545-A1 | TRICYCLIC PYRAZOL AMINE DERIVATIVES | MERCK SERONO SA (CH) | 2012-09-20 | — | — | US | disclosed |
| EP-1009743-A1 | CERTAIN BENZOTHIAZINE DIOXIDE ENDOTHELIN ANTAGONISTS AND PROCESSES FOR THEIR PREPARATION | WARNER-LAMBERT COMPANY (US) | 2000-06-21 | — | — | EP | disclosed |
| EP-0938477-A4 | BENZOTHIAZO AND RELATED HETEROCYCLIC GROUP-CONTAINING CYSTEINE AND SERINE PROTEASE INHIBITORS | CEPHALON INC (US) | 1999-12-29 | — | — | EP | disclosed |
| EP-0938477-A1 | BENZOTHIAZO AND RELATED HETEROCYCLIC GROUP-CONTAINING CYSTEINE AND SERINE PROTEASE INHIBITORS | CEPHALON, INC. (US) | 1999-09-01 | — | — | EP | disclosed |
| WO-1999012916-A1 | CERTAIN BENZOTHIAZINE DIOXIDE ENDOTHELIN ANTAGONISTS AND PROCESSES FOR THEIR PREPARATION | WARNER-LAMBERT COMPANY (US) | 1999-03-18 | — | — | WO | disclosed |
| WO-1998021186-A1 | BENZOTHIAZO AND RELATED HETEROCYCLIC GROUP-CONTAINING CYSTEINE AND SERINE PROTEASE INHIBITORS | CEPHALON, INC. (US) | 1998-05-22 | — | — | WO | disclosed |
| US-4529725-A | 1-Pyridine substituted quino-benzothiazine | ABBOTT LABORATORIES (US) | 1985-07-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120238545-A1 | TRICYCLIC PYRAZOL AMINE DERIVATIVES | PI4KB, MTOR, PI4KA | DAO 3145/4885TSHR 1884/4885NAPRT 2163/4885 |
| US-20020094980-A1 | Certain benzothiazine dioxide endothelin antagonists and processes for their preparation | ECE1, EDNRA, EDNRB | DAO 1053/4885TSHR 1236/4885NAPRT 4098/4885 |
| US-20010036944-A1 | Certain benzothiazine dioxide endothelin antagonists and processes for their preparation | ECE1, EDNRA, EDNRB | DAO 1053/4885TSHR 1236/4885NAPRT 4098/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.